Introduction of long acyl group into either or both hydroxy residue (s) decreased the inhibitory activity. A small acyl moiety such as acetyl or rc-butyryl at the C-l' hydroxy group is responsible for potent inhibitory activity against ACAT. The r-Oacetyl-ll-0-tetrahydropyranyl derivative (l l-0-2"-tetrahydropyranylpurpactin A) showed high selectivity (cytotoxic dose vs. effective dose) in a cell assay using J774 macrophages.
In the course of our screening, we have discovered the novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors, purpactins A, B and C, from the fermentation broth of Penicillium purpurogenum . In this report, we describe the preparation ofpurpactin A derivatives and their ACATinhibitory activity.
Synthesis
Purpactin A (1) was treated with 2,3-dihydropyran in CH2C12 containing 0.25% (w/v) /?-toluensulfonic acid to give 1 l-0-2"-tetrahydropyranyl (THP) ether (3). The treatment of 3 with 1 m LiOH in tetrahydrofuran (THF) gave r-hydroxy-ll-0-2"-THP ether (4). Compound 4 was treated with palmitoyl chloride or rc-butyryl chloride in pyridine to give l'-O-w-butyryl-l l-0-2"-THP ether (4a) and l'-O-palmitoryl-l 1-0-2"-THP ether (4b). By treating 4a or 4b with 1% /7-toluensulfonic acid in MeOH, T-O-palmitoyl (5) and l'-O-rc-butyryl (6) substituents were obtained, respectively (Scheme I). The treatment of 1 with palmitoyl chloride or rc-butyryl chloride in pyridine gave 1 1-0-palmitoyl (7) and 1 1-0-n-butyryl (8) substituents, respectively (Scheme 2). By treating penicillide (2) with one equivalent of «-butyryl chloride or palmitoyl chloride in pyridine, r-hydroxy-l l-0-?2-butyryl (ll) and T-hydroxy-1 1-O-palmitoyl (9) substituents were obtained, respectively (Scheme 3).
The treatment of 2 with excess w-butyryl chloride or palmitoryl chloride in pyridine gave l',ll-0-di-«-butyryl (12) and r,l l-0-dipalrnitoyl (10) substituents, respectively (Scheme 3). 1 1-0-methyl purpactin A (13) was prepared by treating with diazomethane which was described in the previous paper2).
Tetrahydropyranyl derivatives 3 and 4 may be a mixture of the diastereomer at the C-2" position. In XHNMRspectra, the doublet signal of methoxy protons were observed.
On leave from Pfizer Central Research, Nagoya, Pfizer Pharmaceuticals Inc., 5-2 Taketoyo, Aichi 470-23, Japan. Chemical shift values for XHNMRand UVspectral data of all derivatives are described in the Experimental section.
ACAT Inhibitory Activity IC50 values of acyl and other derivatives against ACATactivity both in an enzyme assay using rat liver microsomes and in a cell assay using J774 macrophages are summarized in Tabel 1.
Fromthe results of the enzymeassay, derivatives having a smaller hydrophobic residue at the C-l' hydroxy group (1 and 6) exhibited potent inhibitory activity, though penincillide (2) and the derivative 5, which have no substituent and palmitoyl residue at the hydroxy group, respectively, showedvery weak inhibitory activity. Concerning the C-l l hydroxy group, all derivatives having a long acyl (palmitoyl) group (7, 9 and 10) lost potent inhibitory activity.
The results of inhibitory potency against cholesterol ester formation in J774 cells were essentially similar to those in the enzyme assay. Derivatives having a smaller hydrophobic residue at the C-T and no or a smaller group at the C-M hydroxy group (1, 3, 6 and 8) showed potent inhibitory activity.
Cytotoxicity of these derivatives to J774 cells also tested and the drug concentration showing 50% cell damage (CD50) after 12 hours incubation was measured by trypan blue exclusion method. Amongthem, derivatives 3 and 8 show the highest selectivity ( Fig. 1 and Table 1 ). Under the same conditions, CL-283,5463), a synthetic ACATinhibitor, showed potent inhibitory activity against cholesterol ester formation (IC50: 89nM) and no cytocidal effect at 50fiM in the cell assay. 
Discussion
Known synthetic ACAT inhibitors such as 57-1 184), CL-277,0825) and CL-283,5463) have a long alkyl or acyl moiety in their structures. On the view of this point, acyl or other derivatives at C-T and/or C-l l hydroxy group(s) of penicillide (2) were synthesized. Contrary to our expectation, introduction of a long acyl (palmitoyl) group into at least one of the two hydroxy groups resulted in a decline of the ACAT inhibitory activity. A smaller hydrophobic residue such as acetyl, w-butyryl and THPsubstituted at the C-l' hydroxy moiety is responsible for potent inhibitory activity. In the cell assay, both ACATinhibitory activity as inhibition of cholesterol ester formation (IC50) and cytotoxicity (CD50) were measured at the same time, and the specificity (CD5O/IC5o)of derivatives was calculated. Introduction of w-butyryl or THP group into C-ll resulted in a decline in exhibiting cytotoxicity, suggesting that the C-l l position to play an important role in cytotoxicity. Among derivatives l'-O-acetyl-l l-O-THP (3) and l'-Oacetyl-l l-O-flbutyryl (8) derivatives appeared to show the highest specificity (Table 1 ). It will be interesting to see in vivo efficacy of these derivatives.
Experimental
General Methods NMRspectra were measured with Jeol FX90 and Varian XI-400 spectrometer in CDC13solution. FEB. 1991 MSwas obtained with a Jeol model DX-300spectrometer. UVspectrum was recorded on a Shimadzu UV-200S spectrophotometer. TLC was performed on pre-coated plates, Kieselgel 60 F254 (Merck) with as solvent.
Preparation of Purpactin A (1) and Penicillide (2) Purpactin A and penicillide were prepared as described in the previous paper1}.
Preparation of 3-1'-Acetyloxy-3/-methylbutyl-4-methoxy-9-methyl-
To a solution of 1 (132.6mg, 0.32mmol) in CH2C12 containing 0.25% /?-toluenesulfonic acid (3ml), 2,3-dihydropyrane (400 jil) was added and stirred for 10 minutes at room temperature. The reaction mixture was applied to preparative HPLC (YMCpack AM-324 ODS) and eluted with 80% aq CH3CN. The eluate was evaporated under reduced pressure to afford 3 as a colorless powder (129.5mg, 81.2%): UVAj^H nm (e) 280 (1,900) Preparation of 3-r-Hydroxy-3/-methylbutyl-4-methoxy-9-methyl-l l -2"-tetrahydropyranyloxy-
,5-dioxocin-5-one (4) To a solution of 3 (124.6mg, 0.25mmol) in THF (2ml), 1m LiOH aqueous solution (500/4) was added and stirred for 6 hours at room temperature. The reaction mixture was diluted with H2O(5ml) and extracted with EtOAc (3 x 10 ml). The EtOAc layers were combined and dried over anhydrous sodium sulfate and evaporated under reduced pressure. The residue was applied to preparative HPLC(YMCpack AM-324ODS) and eluted with 80% aq CH3CN. Rf value (CHC13-MeOH, 98 : 2) 035.
Preparation of 3-1 '-Palmitoyloxy-3/-methylbutyl-4-methoxy-9-methyl-1 1 -hydroxy-5//,7#-dibenzo-
To a solution of4 (7.2mg, 0.016mmol) in pyridine (50/zl), palmitoyl chloride (10 pi, 0.036mmol) was added and stirred for 10 minutes at room temperature. The reaction mixture was diluted with H2O(10 ml) and extracted with EtOAc(10 ml). The EtOAc layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure. The residue was applied to preparative HPLC(YMCpack AM-324 ODS, CH3CN) to give a colorless powder (4a, 10.3mg, 94.0%). To a solution of 4a (10.3mg, 0.017mmol) in CH2C12 (50jul), 0.1% /?-toluenesulfonic acid in MeOH(200//I) was added and stirred for 10 minutes at room temperature. The reaction mixture was applied to preparative HPLC(YMCpack AM-324ODS) and eluted with CH3CN. The eluate was evaporated under reduced pressure to afford 5 as a colorless powder Preparation of 3-r-Butyryloxy-3/-methylbutyl-4-methoxy-9-methyll l -hydroxy-5Jy,7i/-dibenzo-
To a solution of 4 (1 1.3 mg, 0.025 mmol) in pyridine (50 /^1), rc-butyryl chloride (5 /jI, 0.047mmol) was added and stirred for 30 minutes at room temperature. The reaction mixture was diluted with H2O (10 ml) and extracted with EtOAc (10 ml). The EtOAc layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure. The residue was applied to preparative HPLC (YMCpack AM-324 ODS, CH3CN) to give a colorless powder (4b, 12.6mg, 90%). To a solution of 4b (12.6mg, 0.022mmol) in CH2C12 (100/il), 0.1%-toluenesulfonic acid in MeOH(lml) was added and stirred for 10 minutes at room temperature. The reaction mixture was evaporated and applied to preparative TLC (CHC13 -MeOH,98 : 2) to afford 6 as a colorless powder (10.0mg, 90%): UV Aá"nm(e) 280 (2,000); EI-MS (mlz) 442 (M)+, 354(M-C4H8O2)+, 298 (M-C4H8O2-C4H8)+, 219 (C13H15O3)+, 163 (C13H15O3-C4H8)+; 1HNMR (90MHz, CDC13) 3 0.80-1.00 (9H, t), 1.00-2.00 (5H, m), 2.22 (3H, s), 2.28 (2H, t), 4.02 (3H, s), 4.98 (1H, d) , 5.14 (1H, d), 6.10 (1H, m), 6.37 (1H, d), 6.82 (1H, d), 6.85 (1H, d), 7.41 (1H, d) , 6.17 (1H, d) ; Rf value (CHC13-MeOH, 98 :2) 0.46.
To a solution of 1 (7.0mg, 0.017 mmol) in pyridine (50 fA), palmitoyl chloride (IOjuI, 0.036mmol) was added and stirred for 30 minutes at room temperature. The reaction mixture was diluted with H2O(5 ml) and extracted with EtOAc (5 ml). The EtOAc layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure. The residue was applied to preparative TLC(CHC13-MeOH, 99 : 1) to afford 7 as a colorless powder (7.8mg, 70%): UV /Lj^nm (e) 280 (1,900); Preparation of 3-r-Acetoxy-3'-methylbutyl-4-methoxy-9-methyll l -rt-butyryloxy-5/7,7//-dibenzo-
To a solution of 1 (lO.Omg, 0.024mmol) in pyridine (50 /zl), «-butyryl chlorid (10 /il, 0.094mmol) was added and stirred for 30 minutes at room temperature. The reaction mixture was diluted with H2O(5 ml) and extracted with EtOAc (5 ml). The EtOAc layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure. Preparation of 3-r-Hydroxy-3/-methylbutyl-4-methoxy-9-methyll l -palmitoyloxy-5/7,7//-dibenzo-
To a solution of 2 (10.0mg, 0.027mmol) in pyridine (100/il), palmitoyl chloride (6.8//!, 0.025mmol) was added and stirred for 30 minutes at room temperature. The reaction mixture was diluted with H2O (5 ml) and extracted with EtOAc (5 ml). The EtOAc layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure. The residue was applied to preparative TLC (CHC13 -MeOH, 99 : 1) to afford 9 as a colorless powder (6.7mg, 41%): UV A^nm (e) 280 (1,900) Preparation of 3-1 % 1 l -Dipalmitoyloxy-3/-methylbutyl-4-methoxy-9-methyl-5i/J//-dibenzo[b,g]-l ,5-dioxocin-5-one (10) To a solution of2 (3.4mg, 0.009mmol) in pyridine (50fA), palmitoyl chloride (10^1, 0.036mmol) was FEB. 1991 added and stirred for 30 minutes at room temperature. The reaction mixture was diluted with H2O(5 ml) and extracted with EtOAc (5 ml). The EtOAc layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure. Preparation of 3-r-Hydroxy-3'-methylbutyl-4-methoxy-9-methyll l -«-butyryloxy-5i/,7i7-dibenzo- [b,g]-l,5-dioxocin-5-one (ll) To a solution of2 (5.0mg, 0.013mmol) in pyridine (50/A), w-butyryl chloride (1.4^1, 0.013mmol) was added and stirred for 30 minutes at room temperature. The reaction mixture was diluted with H2O(5 ml) and extracted with EtOAc(5 ml). The EtOAclayer was dried over anhydrous sodium sulfate and evaporated under reduced pressure. The residue was applied to preparative TLC(CHC13-MeOH,99 : 1) to afford ll as a colorless powder (1.7mg, 29%): UV l^nm (s) 280 (2,000); EI-MS (m/z) 442 (M)+; AH NMR Preparation of 3-r-Acetyloxy-3'-methylbutyl-4-methoxy-l l-methoxy-5/f,7if-dibenzo[b,g]-l ,5-dioxocin-5-one
The preparation of 13 was described in previous paper. Assay for ACATUsing Rat Liver Microsomes ACATactivity was assayed as described in the preceding paper1}.
Assay for Cholesterol Ester Formation in J774 Macrophages
The method for cholesterol ester formation in J774 macrophages and cytotoxicity was described in the preceding paper1*.
